Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: Strength and clinical correlations

Journal of Dermatological Science

Volumn 73, Issue 2, 2014, Pages 101-109

  Hsiao, Yi Hsin ^a   Hui, Rosaline Chung Yee ^a,b   Wu, Tony ^a,b   Chang, Wan Chun ^c   Hsih, Mo Song ^a,b   Yang, Chih Hsun ^a,b   Ho, Hsin Chun ^a,b   Chang, Ya Ging ^a,b   Chen, Ming Jing ^a,b   Lin, Jing Yi ^a,b   Chen, Ding Ping ^a,d   Chang, Pi Yueh ^a,d   Wu, Tsu Lan ^a,d   Hung, Shuen Iu ^c   Chung, Wen Hung ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Carbamazepine; Drug rash with eosinophilia and systemic symptoms; Human leukocyte antigens; Maculopapular exanthema; Stevens Johnson syndrome

Indexed keywords

CARBAMAZEPINE; HLA A ANTIGEN; HLA B ANTIGEN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BODY SURFACE; CHILD; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; ERYTHEMA MULTIFORME; FEMALE; FIXED DRUG ERUPTION; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HLA A GENE; HLA B GENE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOLYMPHOMA; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VERY ELDERLY;

BODY SURFACE AREA; BSA; CARBAMAZEPINE; CBZ; CI; CONFIDENCE INTERVAL; DIHS; DRESS; DRUG INDUCED HYPERSENSITIVITY SYNDROME; DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS; EM; ERYTHEMA MULTIFORME; FDE; FIXED DRUG ERUPTION; HLA; HUMAN LEUKOCYTE ANTIGEN; HUMAN LEUKOCYTE ANTIGENS; MACULOPAPULAR EXANTHEMA; MPE; ODDS RATIO; OR; SJS; STEVENS-JOHNSON SYNDROME; TEN; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHINA; COHORT STUDIES; DRUG HYPERSENSITIVITY; EOSINOPHILIA; EXANTHEMA; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B15 ANTIGEN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHARMACOGENETICS; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84891663151     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.10.003     Document Type: Article

References (39)

1. Gamble C., Williamson P.R., Chadwick D.W., Marson A.G. A meta analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006, 66:1310-1317.
2. Mockenhaupt M., Messenheimer J., Tennis P., Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005, 64:1134-1138.
3. Yang C.Y., Dao R.L., Lee T.J., Lu C.W., Yang C.H., Hung S.I., et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011, 77:2025-2033.
4. Roujeau J.C. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005, 209:123-129.
5. Ardern-Jones M.R., Friedmann P.S. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011, 71:672-683.
6. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
7. Hung S.I., Chung W.H., Jee S.H., Chen W.C., Chang Y.T., Lee W.R., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
8. Locharernkul C., Loplumlert J., Limotai C., Korkij W., Desudchit T., Tongkobpetch S., et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008, 49:2087-2091.
9. Mehta T.Y., Prajapati L.M., Mittal B., Joshi C.G., Sheth J.J., Patel D.B., et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009, 75:579-582.
10. Chang C.C., Too C.L., Murad S., Hussein S.H. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011, 50:221-224.
11. Lonjou C., Thomas L., Borot N., Ledger N., de Toma C., LeLouet H., et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006, 6:265-268.
12. Lonjou C., Borot N., Sekula P., Ledger N., Thomas L., Halevy S., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107.
13. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., et al. HLAB*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2011, 51:2461-2465.
14. Kim S.H., Lee K.W., Song W.J., Kim S.H., Jee Y.K., Lee S.M., et al. Carbamazepine induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011, 97:190-197.
15. Ferrell P.B., McLeod H.L., Carbamazepine HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA Recommendations. Pharmacogenomics 2008, 9:1543-1546.
16. Chen P., Lin J.J., Lu C.S., Ong C.T., Hsieh P.F., Yang C.C., et al. Carbamazepine-induce toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
17. McCormack M., Alfirevic A., Bourgeois S., Farrell J.J., Kasperavičiūtė D., Carrington M., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
18. Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011, 20:1034-1041.
19. Phillips E.J., Chung W.H., Mockenhaupt M., Roujeau J.C., Mallal S.A. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011, 127:S60-S66.
20. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
21. Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K., et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010, 88:60-68.
22. Roujeau J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994, 102:28S-30S.
23. Auquier-Dunant A., Mockenhaupt M., Naldi L., Correia O., Schröder W., Roujeau J.C., et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002, 138:1019-1024.
24. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609-611.
25. Cacoub P., Musette P., Descamps V., Meyer O., Speirs C., Finzi L., et al. The DRESS syndrome: a literature review. Am J Med 2011, 124:588-597.
26. Shiohara T., Mizukawa Y. Fixed drug eruption: easily overlooked but needing new respect. Dermatology 2002, 205:103.
27. Lee C.H., Chen Y.C., Cho Y.T., Chang C.Y., Chu C.Y. Fixed-drug eruption: a retrospective study in a single referral center in northern Taiwan. Dermatol Sin 2012, 30:11-15.
28. Albrecht J., Fine L.A., Piette W. Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin 2007, 25:233-244.
29. Meyer Sauteur P.M., Gansser-Kalin U., Lautenschlager S., Goetschel P. Fuchs syndrome associated with Mycoplasma pneumoniae (Stevens-Johnson syndrome without skin lesions). Pediatr Dermatol 2011, 28:474-476.
30. Maceneaney P.M., Malone D.E. The meaning of diagnostic test results: a spreadsheet for swift data analysis. Clin Radiol 2000, 55:227-235.
31. Chen P.L., Fann C.S., Chu C.C., Chang C.C., Chang S.W., Hsieh H.Y., et al. Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles. PLoS One 2011, 6(1):e16635.
32. The allele frequency net database ( [accessed 20.08.13]). http://www.allelefrequencies.net/.
33. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
34. Gueudry J., Roujeau J.C., Binaghi M., Soubrane G., Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009, 145:157-162.
35. Tassaneeyakul W., Tiamkao S., Jantararoungtong T., Chen P., Lin S.Y., Chen W.H., et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010, 51:926-930.
36. Liao W.P., Shi Y.W., Min F.L. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med 2011, 365:672-673. (author reply 673).
37. Wei C.Y., Chung W.H., Huang H.W., Chen Y.T., Hung S.I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012, 169:1562-1569.
38. Ko T.M., Chung W.H., Wei C.Y., Shih H.Y., Chen J.K., Lin C.H., et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011, 128:1266-1276.
39. Chung W.H., Hung S.I. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci 2012, 66:190-196.